Thermal ablation is heating tumors so hot that the tumor cells die. It has been studied in many forms, including microwave, laser, high-intensity focused ultrasound, and cryotherapy (freezing below -20 C). Radiofrequency thermal ablation or radiofrequency ablation (RFA) has emerged as the most commonly used technology for thermal ablation in the bone, liver, kidney, lung, heart, breast, lymph nodes, nerve ganglia, and soft tissue.
New research suggests that sedating patients before a nerve block needed to diagnose or treat chronic pain increases costs, risks and unnecessary surgeries, and sedation does nothing to increase patient satisfaction or long-term pain control.
Not prescribing opioids first or as a long-term therapy for chronic, non-cancer pain and avoiding MRIs, CTs and X-rays for low-back pain are among the tests and treatments identified by ASA that are commonly ordered but not always necessary.
A systematic review of 66 research papers focused on the treatment of skin ulcers suggests that most are so technically flawed that their results are unreliable. And even of those that pass muster, there is only weak evidence that some treatments work better than standard compression therapy or special stockings.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF.
Radiofrequency ablation (RFA) leads to remission for 91 percent of patients with dysplastic Barrett's esophagus, according to new figures published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
A joint consensus statement on the treatment of paediatric arrhythmias has been released by the European Heart Rhythm Association of the European Society of Cardiology and the Association for European Paediatric and Congenital Cardiology.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation during last week's International Society for Minimally Invasive Cardiothoracic Surgery meeting being held in Prague, Czech Republic.
Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation reduces blood pressure in patients who do not respond to conventional drug therapy.
First-of-its-kind research presented today showed microwave ablation therapy cut pain in half for patients with painful bone and soft-tissue tumors and took less time to complete than radiofrequency ablation.
Researchers at the University of California, San Diego School of Medicine have released study results that show national treatment trends in the surgical management of patients with kidney disease.
According to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania, patients with Barrett's esophagus and early or pre-cancerous cells have been shown to significantly benefit from minimally invasive therapy delivered through an endoscope - a medical instrument used to look inside an organ or cavity in the body.
Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.
Nephron-sparing surgery is more effective than ablation for the treatment of clinical stage T1a renal masses, research findings show.
InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain.
Elbit Imaging Ltd. announced today that on December 3, 2012, Elbit Medical Technologies Ltd., announced that InSightec Ltd. has been awarded the European CE mark for its transcranial focused ultrasound system, ExAblate Neuro, with respect to the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain.
The Department of Nuclear Medicine at the Frankfurt University Hospital recently became the first European hospital to use microwaves to ablate thyroid nodules.
A new study shows that endoscopic mucosal resection (EMR) before radiofrequency ablation (RFA) is a safe and effective treatment option for patients with nodular Barrett's esophagus (BE) and advanced neoplasia.
Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein.
ReCor Medical, an emerging medical device company, reported today six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the Company's PARADISE System—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.